CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
Hyun Jin Oh, Mun Sung Cho, Jae Wook Lee, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho, Hack-Ki Kim
Clin Exp Pediatr. 2013;56(8):343-350.   Published online August 27, 2013
DOI: https://doi.org/10.3345/kjp.2013.56.8.343

Excel Download

Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia
Hyun Jin Oh, Mun Sung Cho, Jae Wook Lee, Pil-Sang Jang, Nack-Gyun Chung, Bin Cho, Hack-Ki Kim
Korean Journal of Pediatrics. 2013;56(8):343   Crossref logo
Link1
Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia
Michihiro Uchiyama, Takashi Ikeda
Leukemia Research. 2009;33(12):1723-1724   Crossref logo
Link1 Link2
Interleukin 11 May improve thrombocytopenia associated with Imatinib mesylate therapy in chronic Myelogenous leukemia
Patricia Ault, Hagop Kantarjian, Mary Alma Welch, Francis Giles, Mary Beth Rios, Jorge Cortes
Leukemia Research. 2004;28(6):613-618   Crossref logo
Link1 Link2
Response of concomitant chronic myelogenous leukemia and chronic lymphocytic leukemia to imatinib mesylate
Ju-Yoon Yoon, Rajat Kumar, Raquel Aloyz, James B. Johnston
Leukemia Research. 2011;35(9):e179-e180   Crossref logo
Link1 Link2
Occurrences of opportunistic infections in chronic myelogenous leukemia patients treated with imatinib mesylate
Navin Anthony, James Shanks, Howard Terebelo
Leukemia Research. 2010;34(9):1250-1251   Crossref logo
Link1 Link2
Imatinib mesylate discontinuation in patients with chronic myeloid leukemia who have received front-line imatinib mesylate therapy and achieved complete molecular response
Ho-Young Yhim, Na-Ri Lee, Eun-Kee Song, Chang-Yeol Yim, So Yeon Jeon, Seunghwan Shin, Jeong-A Kim, Hee Sun Kim, Eun Hae Cho, Jae-Yong Kwak
Leukemia Research. 2012;36(6):689-693   Crossref logo
Link1 Link2
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines
Pengliang Xin, Chuntuan Li, Yan Zheng, Qunyi Peng, Huifang Xiao, Yuanling Huang, Xiongpeng Zhu
Drug Design, Development and Therapy. 2017;Volume11:1115-1126   Crossref logo
Link1 Link2
Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia
Maynika V. Rastogi, Linda Stork, Brian Druker, Carolyn Blasdel, Thuan Nguyen, Bruce A. Boston
Pediatric Blood & Cancer. 2012;59(5):840-845   Crossref logo
Link1 Link2 Link3
Molecular Responses in Patients With Chronic Myelogenous Leukemia in Chronic Phase Treated With Imatinib Mesylate
M.S. Gordon
Yearbook of Medicine. 2006;2006:164-165   Crossref logo
Link1 Link2
Molecular Responses in Patients With Chronic Myelogenous Leukemia in Chronic Phase Treated With Imatinib Mesylate
M.S. Gordon
Yearbook of Oncology. 2006;2006:176-177   Crossref logo
Link1 Link2